Tags

Type your tag names separated by a space and hit enter

Yellow fever vaccine: past, present and future.
Expert Opin Biol Ther. 2008 Nov; 8(11):1787-95.EO

Abstract

BACKGROUND

Yellow fever is a re-emerging infectious disease, as vector control and routine immunisation have dwindled in endemic areas in the last few decades. There is a constant threat of outbreaks in the large susceptible non-immune population of the megacities in tropical countries with an ongoing virus life cycle in the rainforests. For this population and for travellers to endemic areas, vaccination is the only effective protective measure against the disease and the spread of the virus.

OBJECTIVE/METHODS

We discuss the history of yellow fever vaccine development, and focus on practical aspects of vaccine safety, contraindications for vaccination, and future vaccine developments.

RESULTS/CONCLUSIONS

Vaccination with the live attenuated yellow fever-17D vaccine (YF-17D) induces low-grade viraemia in half of the vaccinees and elicits protective neutralising antibody levels in 99%. Reports of serious adverse events in the elderly and immunocompromised, and the inability to produce large quantities of yellow fever vaccine at short notice in combination with limited vaccine stockpiles highlight the need for further study of this highly effective and safe vaccine.

Authors+Show Affiliations

Leiden University Medical Center, Department of Infectious Diseases, Leiden, Netherlands.No affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

18847312

Citation

Roukens, Anna H., and Leo G. Visser. "Yellow Fever Vaccine: Past, Present and Future." Expert Opinion On Biological Therapy, vol. 8, no. 11, 2008, pp. 1787-95.
Roukens AH, Visser LG. Yellow fever vaccine: past, present and future. Expert Opin Biol Ther. 2008;8(11):1787-95.
Roukens, A. H., & Visser, L. G. (2008). Yellow fever vaccine: past, present and future. Expert Opinion On Biological Therapy, 8(11), 1787-95. https://doi.org/10.1517/14712598.8.11.1787
Roukens AH, Visser LG. Yellow Fever Vaccine: Past, Present and Future. Expert Opin Biol Ther. 2008;8(11):1787-95. PubMed PMID: 18847312.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Yellow fever vaccine: past, present and future. AU - Roukens,Anna H, AU - Visser,Leo G, PY - 2008/10/14/pubmed PY - 2009/2/4/medline PY - 2008/10/14/entrez SP - 1787 EP - 95 JF - Expert opinion on biological therapy JO - Expert Opin Biol Ther VL - 8 IS - 11 N2 - BACKGROUND: Yellow fever is a re-emerging infectious disease, as vector control and routine immunisation have dwindled in endemic areas in the last few decades. There is a constant threat of outbreaks in the large susceptible non-immune population of the megacities in tropical countries with an ongoing virus life cycle in the rainforests. For this population and for travellers to endemic areas, vaccination is the only effective protective measure against the disease and the spread of the virus. OBJECTIVE/METHODS: We discuss the history of yellow fever vaccine development, and focus on practical aspects of vaccine safety, contraindications for vaccination, and future vaccine developments. RESULTS/CONCLUSIONS: Vaccination with the live attenuated yellow fever-17D vaccine (YF-17D) induces low-grade viraemia in half of the vaccinees and elicits protective neutralising antibody levels in 99%. Reports of serious adverse events in the elderly and immunocompromised, and the inability to produce large quantities of yellow fever vaccine at short notice in combination with limited vaccine stockpiles highlight the need for further study of this highly effective and safe vaccine. SN - 1744-7682 UR - https://www.unboundmedicine.com/medline/citation/18847312/Yellow_fever_vaccine:_past_present_and_future_ L2 - https://www.tandfonline.com/doi/full/10.1517/14712598.8.11.1787 DB - PRIME DP - Unbound Medicine ER -